In the past week, ALLR stock has gone up by 1.01%, with a monthly gain of 11.79% and a quarterly surge of 9.88%. The volatility ratio for the week is 5.97%, and the volatility levels for the last 30 days are 7.73% for Allarity Therapeutics Inc The simple moving average for the past 20 days is 9.54% for ALLR’s stock, with a -15.77% simple moving average for the past 200 days.
Is It Worth Investing in Allarity Therapeutics Inc (NASDAQ: ALLR) Right Now?
The stock has a 36-month beta value of 0.01. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALLR is 11.53M, and at present, short sellers hold a 5.65% of that float. On July 03, 2025, the average trading volume of ALLR was 816.55K shares.
ALLR) stock’s latest price update
The stock price of Allarity Therapeutics Inc (NASDAQ: ALLR) has dropped by -3.85% compared to previous close of $1.04. Despite this, the company has seen a gain of 1.01% in its stock price over the last five trading days. globenewswire.com reported 2025-06-27 that TARPON SPRINGS, Fla., June 27, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
ALLR Trading at 1.49% from the 50-Day Moving Average
After a stumble in the market that brought ALLR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.58% of loss for the given period.
Stock Fundamentals for ALLR
The total capital return value is set at -1.39. Equity return is now at value -383.74, with -112.25 for asset returns.
Currently, EBITDA for the company is -27.24 million with net debt to EBITDA at 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.66.
Conclusion
To sum up, Allarity Therapeutics Inc (ALLR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
